The stock of Cytosorbents Corp (NASDAQ:CTSO) is a huge mover today! About 77,272 shares traded hands. Cytosorbents Corp (NASDAQ:CTSO) has risen 27.81% since April 5, 2016 and is uptrending. It has outperformed by 25.85% the S&P500.
The move comes after 9 months positive chart setup for the $138.61 million company. It was reported on Nov, 8 by Barchart.com. We have $11.33 PT which if reached, will make NASDAQ:CTSO worth $146.93M more.
Analysts await Cytosorbents Corp (NASDAQ:CTSO) to report earnings on November, 11. They expect $-0.11 EPS, 0.00% or $0.00 from last year’s $-0.11 per share. After $-0.12 actual EPS reported by Cytosorbents Corp for the previous quarter, Wall Street now forecasts -8.33% EPS growth.
Cytosorbents Corp (NASDAQ:CTSO) Ratings Coverage
Out of 4 analysts covering CytoSorbents (NASDAQ:CTSO), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. CytoSorbents has been the topic of 4 analyst reports since October 29, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by B. Riley & Co given on Friday, October 7. The rating was initiated by Aegis Capital on Wednesday, October 26 with “Buy”. The stock has “Buy” rating given by Maxim Group on Tuesday, May 24. The stock has “Buy” rating given by WBB Securities on Thursday, October 29.
According to Zacks Investment Research, “CytoSorbents Corporation is a therapeutic medical device company. It develops adsorbent polymer technology for applications in the medical field, primarily to provide blood purification for the treatment of acute and chronic health complications associated with blood toxicity. The Company’s product include CytoSorb, which filters cytokines and treat potentially fatal cytokine storm and BetaSorb, which remove beta2-microglobulin from the blood of patients suffering from chronic kidney failure. CytoSorbents Corporation is headquartered in Monmouth Junction, New Jersey.”
Insitutional Activity: The institutional sentiment decreased to 0.79 in 2016 Q2. Its down 0.07, from 0.86 in 2016Q1. The ratio fall, as 7 funds sold all Cytosorbents Corp shares owned while 7 reduced positions. 4 funds bought stakes while 7 increased positions. They now own 1.36 million shares or 2.40% less from 1.40 million shares in 2016Q1.
Retail Bank Of America De has invested 0% of its portfolio in Cytosorbents Corp (NASDAQ:CTSO). Bank & Trust Of New York Mellon Corp reported 29,469 shares or 0% of all its holdings. Northern Tru accumulated 23,709 shares or 0% of the stock. Glenmede Trust Na has invested 0% of its portfolio in Cytosorbents Corp (NASDAQ:CTSO). Creative Planning, a Kansas-based fund reported 5,500 shares. Blackrock Fund holds 0% or 53,915 shares in its portfolio. Ladenburg Thalmann Services reported 24,069 shares or 0% of all its holdings. The United Kingdom-based Barclays Pcl has invested 0% in Cytosorbents Corp (NASDAQ:CTSO). Geode Ltd Co has 125,772 shares for 0% of their US portfolio. Moreover, Blackrock Institutional Tru Com Na has 0% invested in Cytosorbents Corp (NASDAQ:CTSO) for 26,460 shares. Kcg Incorporated has invested 0% of its portfolio in Cytosorbents Corp (NASDAQ:CTSO). Blackrock Advsrs Lc has invested 0% of its portfolio in Cytosorbents Corp (NASDAQ:CTSO). Susquehanna International Gp Limited Liability Partnership last reported 0% of its portfolio in the stock. Deutsche Commercial Bank Ag, a Germany-based fund reported 75 shares. Blackrock Investment Mngmt Ltd Com holds 3,776 shares or 0% of its portfolio.
Insider Transactions: Since June 7, 2016, the stock had 2 buys, and 0 selling transactions for $39,090 net activity. BATOR MICHAEL G. also bought $14,640 worth of Cytosorbents Corp (NASDAQ:CTSO) shares. On Wednesday, August 24 Chan Phillip P. bought $24,450 worth of the stock or 5,000 shares.
More notable recent Cytosorbents Corp (NASDAQ:CTSO) news were published by: Marketwatch.com which released: “Cytosorbents Corp.” on April 21, 2011, also Prnewswire.com with their article: “CytoSorbents Congratulates Kathleen Bloch as NJBIZ Public Company Chief …” published on October 17, 2016, Fool.com published: “Why Cytosorbents Corp Shares Burst Today” on April 01, 2015. More interesting news about Cytosorbents Corp (NASDAQ:CTSO) were released by: Prnewswire.com and their article: “CytoSorbents to Present at the 2016 Rodman & Renshaw Annual Global Investment …” published on September 07, 2016 as well as Prnewswire.com‘s news article titled: “CytoSorbents to Present at the 2016 BIO Investor Forum” with publication date: October 14, 2016.
CTSO Company Profile
CytoSorbents Corporation, incorporated on April 25, 2002, is a critical care focused immunotherapy company. The Firm is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company’s CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery, autoimmune disease flares, cancer, cytokine release syndrome in cancer immunotherapy and cancer cachexia.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.